Dyslipidemia Associated with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Cardiovascular disease is a major cause of morbidity and mortality in patients with impaired renal function. Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease (CVD) in the general population and it is well known that patients with chronic kidney disease (CKD) exhibit significant alterations in lipoprotein metabolism. In this review, the pathogenesis and treatment of CKD-induced dyslipidemia are discussed. Studies on lipid abnormalities in predialysis, hemodialysis and peritoneal dialysis patients are analyzed. In addition, the results of the studies that tested the effects of the hypolipidemic drugs on cardiovascular morbidity and mortality in patients with CKD are reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992 · cited 1×
“The same results were also obtained by the study of the prespecified subgroups of individuals with impaired renal function in the HPS [109, 119] and ASCOT-LLA [120] studies that utilized simvastatin and atorvastatin, respectively.”
ResultClinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958 · cited 1×
“In patients who finally advance to ESRD and especially dialysis patients, the prevalence of clinical coronary heart disease is 40% and CVD mortality is 10 to 30 times higher than in the general population of the same gender, age and race [5, 9, 10].”
BackgroundSever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Sarnak, M. J., Levey, A. S., Schoolwerth, A. C., Coresh, J., Culleton, B., Hamm, L. L., McCullough, P. A., Kasiske, B. L., Kelepouris, E., Klag, M. J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000095676.90936.80 · Cited by 3,768 · cited 4×
“Mild chronic impaired renal function contributes actively to the development of CVD, so the American Heart Association has recommended that these patients should be classified in the highest risk group for developing cardiovascular events [5].”
BackgroundInfluentialAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61778-4 · Cited by 2,331 · cited 3×
“[17] Lewington S, Whitlock G, Clarke R, et al.”
BackgroundInfluentialRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 2×
“The publication of the results of AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) study few months ago [127], led to the conception of “a point of no return”, i.”
BackgroundLowrie, E. G., & Lew, N. L. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70364-5 · Cited by 1,976 · cited 1×
“Finally, some other studies suggested an inverse relationship between serum cholesterol values and mortality in ESRD individuals, a phenomenon also known as “reverse epidemiology” [101, 103, 104].”
BackgroundStrong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
Stenvinkel, P., Heimbürger, O., Paultre, F., Diczfalusy, U., Wang, T., Berglund, L., & Jogestrand, T. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00422.x · Cited by 1,778 · cited 2×
“[81] Stenvinkel P, Heimburger O, Paultre F, et al.”
BackgroundInflammation enhances cardiovascular risk and mortality in hemodialysis patients
Zimmermann, J., Herrlinger, S., Pruy, A., Metzger, T., & Wanner, C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00273.x · Cited by 1,531 · cited 2×
“The malnutrition and inflammation and, mainly, the decreased clearance of apo(a) in HD patients, have been implicated in this procedure [80-83].”
BackgroundSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Chertow, G. M., Burke, S. K., Raggi, P., & for the Treat to Goal Working Group (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00434.x · Cited by 1,462 · cited 1×
“It has been shown that sevelamer hydrochloride significantly reduces the concentrations of total cholesterol and apolipoprotein B in HD patients [68].”
BackgroundMultiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
Wang, T. J., Gona, P., Larson, M. G., Tofler, G. H., Levy, D., Newton-Cheh, C., Jacques, P. F., Rifai, N., Selhub, J., Robins, S. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055373 · Cited by 1,343 · cited 2×
“[14] Wang TJ, Gona P, Larson MG, et al.”
BackgroundReverse epidemiology of cardiovascular risk factors in maintenance dialysis patients
Kalantar-Zadeh, K., Block, G., Humphreys, M. H., & Kopple, J. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00803.x · Cited by 1,247 · cited 2×
“[103] Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD.”
BackgroundThe elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179 · cited 2×
“[13] Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM.”
BackgroundUtermann, G., Menzel, H. J., Kraft, H. G., Duba, H. C., Kemmler, H. G., & Seitz, C. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113093 · Cited by 881 · cited 2×
“[70] Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz”
BackgroundLiu, Y., Coresh, J., Eustace, J. A., Longenecker, J. C., Jaar, B., Fink, N. E., Tracy, R. P., Powe, N. R., & Klag, M. J. (2004) · JAMA · doi:10.1001/jama.291.4.451 · Cited by 777 · cited 3×
“Although the precise causes of this significant deviation from what is observed in the general population have not been established, it has been proposed that the presence of phenomena such as inflammation or protein energy wasting (conditions very common in ESRD patients) may significantly confound the relationship b…”
BackgroundResultChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A., Chertow, G., & Fan, D. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.10.020 · Cited by 773 · cited 2×
“Thus, although some patients with CKD will ultimately develop end stage renal disease (ESRD), most patients with CKD will die of CVD before dialysis becomes necessary [7].”
BackgroundShlipak, M. G., Fried, L. F., Cushman, M., Manolio, T. A., Peterson, D., Stehman-Breen, C., Bleyer, A., Newman, A., Siscovick, D., & Psaty, B. (2005) · JAMA · doi:10.1001/jama.293.14.1737 · Cited by 735 · cited 2×
“[102] Shlipak MG, Fried LF, Cushman M, et al.”
BackgroundInternational Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk
Hallan, S. I., Coresh, J., Astor, B. C., A[Combining Ring Above]sberg, A., Powe, N. R., Romundstad, S., Hallan, H. A., Lydersen, S., & Holmen, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121273 · Cited by 699 · cited 2×
“[6] Hallan SI, Coresh J, Astor BC, et al.”
BackgroundPremature cardiovascular disease in chronic renal failure
Baigent, C., Burbury, K., & Wheeler, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02456-9 · Cited by 581 · cited 1×
“On the other hand, it is well documented that cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with CKD [2-6].”
BackgroundMortality Risk Factors in Patients Treated by Chronic Hemodialysis
Degoulet, P., Legrain, M., Réach, I., Aimé, F., Devriès, C., Rojas, P., & Jacobs, C. (1982) · Nephron · doi:10.1159/000182627 · Cited by 529 · cited 3×
“[101] Degoulet P, Legrain M, Reach I, et al.”
BackgroundHonda, H., Qureshi, A. R., Heimbürger, O., Barany, P., Wang, K., Pecoits-Filho, R., Stenvinkel, P., & Lindholm, B. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.09.014 · Cited by 510
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408 · cited 2×
“[132] Davidson MH, Armani A, McKenney JM, Jacobson TA.”
BackgroundDavidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385 · cited 2×
“The administration of omega-3 polyunsaturated fatty acids may also have a role in the management of this extremely rare condition [134].”
BackgroundHypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients
Iseki, K., Yamazato, M., Tozawa, M., & Takishita, S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00324.x · Cited by 383 · cited 3×
“Although the precise causes of this significant deviation from what is observed in the general population have not been established, it has been proposed that the presence of phenomena such as inflammation or protein energy wasting (conditions very common in ESRD patients) may significantly confound the relationship b…”
BackgroundResultEffect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease
Tonelli, M., Isles, C., Curhan, G. C., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C., Cobbe, S. M., Simes, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000143892.84582.60 · Cited by 381 · cited 2×
“Indeed, in several large, prospective, placebo-controlled trials of statins, post hoc analyses of subgroups with mild to moderate CKD (stages 1-3) revealed a significant reduction in cardiovascular morbidity and mortality independently of the baseline lipid values and the presence or the absence of diabetes and corona…”
BackgroundInsulin resistance and hyperinsulinemia are already present in patients with incipient renal disease
Fliser, D., Pacini, G., Engelleiter, R., Kautzky-Willer, A., Prager, R., Franek, E., & Ritz, E. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00898.x · Cited by 359 · cited 3×
“It is well known that CKD causes insulin resistance which can, in turn, promote hepatic VLDL production [23-25].”
BackgroundLipoprotein Metabolism and Renal Failure
Attman, P.-O., Samuelsson, O., & Alaupovic, P. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80030-8 · Cited by 355 · cited 2×
“[90] Attman PO, Samuelsson O, Alaupovic P.”
BackgroundLipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354 · cited 3×
“Hypertriglyceridemia is one of the most common quantitative lipid abnormalities in patients with CKD [20-22].”
BackgroundAntiatherogenic small, dense HDL—guardian angel of the arterial wall?
Kontush, A., & Chapman, M. J. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0500 · Cited by 342 · cited 2×
“Moreover, HDL serves as a potent endogenous inhibitor of inflammation, platelet adhesion and LDL oxidation, because of a number of HDL associated apolipoproteins (mainly apolipoprotein AI) and enzymes (paroxonase-1, platelet-activating factor acetylhydrolase and lecithin-cholesterol acyltransferase (LCAT) [88].”
BackgroundHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Outcome and risk factors of ischemic heart disease in chronic uremia
Parfrey, P. S., Foley, R. N., Harnett, J. D., Kent, G. M., Murray, D., & Barre, P. E. (1996) · Kidney International · doi:10.1038/ki.1996.201 · Cited by 325 · cited 2×
“[9] Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE.”
BackgroundHDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study
Després, J.-P., Lemieux, I., Dagenais, G.-R., Cantin, B., & Lamarche, B. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00603-1 · Cited by 316 · cited 2×
“Several epidemiological studies have demonstrated that HDL cholesterol is a negative risk factor for atheroscerosis [89].”
BackgroundShepherd, J., Kastelein, J. J. P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., & Wenger, N. K. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.11.072 · Cited by 302 · cited 2×
“Indeed, in several large, prospective, placebo-controlled trials of statins, post hoc analyses of subgroups with mild to moderate CKD (stages 1-3) revealed a significant reduction in cardiovascular morbidity and mortality independently of the baseline lipid values and the presence or the absence of diabetes and corona…”
BackgroundHMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
Seliger, S. L., Weiss, N. S., Gillen, D. L., Kestenbaum, B., Ball, A., Sherrard, D. J., & Stehman-Breen, C. O. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00109.x · Cited by 294 · cited 3×
“[122] Seliger SL, Weiss NS, Gillen DL, et al.”
BackgroundResultTonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278 · cited 2×
“Indeed, in several large, prospective, placebo-controlled trials of statins, post hoc analyses of subgroups with mild to moderate CKD (stages 1-3) revealed a significant reduction in cardiovascular morbidity and mortality independently of the baseline lipid values and the presence or the absence of diabetes and corona…”
BackgroundMagnus, P., & Beaglehole, R. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.22.2657 · Cited by 277 · cited 1×
“Although most of the cases of coronary heart disease in the general population can be explained by traditional, Framingham risk factors [12], in patients with CKD, uremia related, non -traditional risk factors, such as, inflammation, oxidative stress, anemia, malnutrition, vascular calcification (due to alterations in…”
BackgroundKRONENBERG, F., KUEN, E., RITZ, E., JUNKER, R., KO[Combining Diaeresis]NIG, P., KRAATZ, G. D., LHOTTA, K., MANN, J. F. E., MU[Combining Diaeresis]LLER, G. A., NEYER, U., et al. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v111105 · Cited by 248
Association between Serum Lipids and Survival in Hemodialysis Patients and Impact of Race
Kilpatrick, R. D., McAllister, C. J., Kovesdy, C. P., Derose, S. F., Kopple, J. D., & Kalantar-Zadeh, K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070795 · Cited by 233 · cited 1×
“[107] Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K.”
Kronenberg, F., König, P., Neyer, U., Auinger, M., Pribasnig, A., Lang, U., Reitinger, J., Pinter, G., Utermann, G., & Dieplinger, H. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v61110 · Cited by 233
K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.
(2003) · PubMed · Cited by 228
Tonelli, M., Bohm, C., Pandeya, S., Gill, J., Levin, A., & Kiberd, B. A. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80004-4 · Cited by 216
Whaley-Connell, A. T., Sowers, J. R., Stevens, L. A., McFarlane, S. I., Shlipak, M. G., Norris, K. C., Chen, S.-C., Qiu, Y., Wang, C., Li, S., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.12.016 · Cited by 203 · cited 1×
“[1] Whaley-Connell AT, Sowers JR, Stevens LA, et al.”
Van Biesen, W., De Bacquer, D., Verbeke, F., Delanghe, J., Lameire, N., & Vanholder, R. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl455 · Cited by 179 · cited 2×
“[3] Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R.”
BackgroundSelective Deficiency of Hepatic Triglyceride Lipase in Uremic Patients
Mordasini, R., Frey, F., Flury, W., Klose, G., & Greten, H. (1977) · New England Journal of Medicine · doi:10.1056/nejm197712222972502 · Cited by 172 · cited 2×
“[40] Mordasini R, Frey F, Flury W, Klose G, Greten H.”
BackgroundResultKoch, M., Kutkuhn, B., Trenkwalder, E., Bach, D., Grabensee, B., Dieplinger, H., & Kronenberg, F. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v8121889 · Cited by 165
Mason, N. A., Bailie, G. R., Satayathum, S., Bragg-Gresham, J. L., Akiba, T., Akizawa, T., Combe, C., Rayner, H. C., Saito, A., Gillespie, B. W., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.09.025 · Cited by 158 · cited 2×
“Although epidemiological studies have shown that the use of statins in individuals receiving maintenance hemodialysis is accompanied by a reduction in cardiovascular mortality [122-124], the prospective, randomized trials that tested the potential beneficial effect of statins in this patient population revealed disapp…”
BackgroundResultWanner, C., Krane, V., März, W., Olschewski, M., Asmus, H.-G., Krämer, W., Kühn, K.-W., Kütemeyer, H., Mann, J. F. E., Ruf, G., et al. (2004) · Kidney and Blood Pressure Research · doi:10.1159/000080241 · Cited by 157 · cited 1×
“The 4D (Die Deutsche Diabetes Dialyse) trial enrolled 1255 diabetic subjects who had been on maintenance HD for less than 2 years and were randomized to receive either placebo or 20 mg/day of atorvastatin [125].”
MethodKRONENBERG, F., NEYER, U., LHOTTA, K., TRENKWALDER, E., AUINGER, M., PRIBASNIG, A., MEISL, T., KÖNIG, P., & DIEPLINGER, H. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1051027 · Cited by 155
Bagdade, J. D., Casaretto, A., & Albers, J. J. (1976) · PubMed · Cited by 153
Molecular mechanisms of lipid disorders in nephrotic syndrome
Vaziri, N. D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00941.x · Cited by 152 · cited 1×
“In contrast, patients with nephrotic range proteinuria, exhibit an acquired LDL-receptor deficiency [52].”
BackgroundElevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome
Wanner, C., Rader, D., Bartens, W., Kramer, J., Brewer, H. B., Schollmeyer, P., & Wieland, H. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00002 · Cited by 149 · cited 2×
“[86] Wanner C, Rader D, Bartens W, et al.”
BackgroundVaziri, N. D., Liang, K., & Parks, J. S. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00734.x · Cited by 147 · cited 1×
“Thus, patients with impaired renal function usually exhibit decreased levels of apolipoproteins AI and AII (the main protein constituents of HDL) [91], diminished activity of LCAT (the enzyme responsible for the esterification of free cholesterol in HDL particles) [92, 93], as well as increased activity of cholesteryl…”
BackgroundDyslipidemia in Chronic Kidney Disease: An Approach to Pathogenesis and Treatment
Tsimihodimos, V., Dounousi, E., & Siamopoulos, K. C. (2008) · American Journal of Nephrology · doi:10.1159/000144024 · Cited by 146 · cited 2×
“CKD is characterized by specific metabolic abnormalities of plasma lipoproteins [18, 19].”
BackgroundSelf-citationDeighan, C. J., CASLAKE, M. J., McConnell, M., Boulton‐Jones, J. M., & Packard, C. J. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70255-1 · Cited by 140 · cited 4×
“[60] Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ.”
BackgroundInfluentialMechanisms of dyslipidemia of chronic renal failure
Vaziri, N. D., & Moradi, H. (2006) · Hemodialysis International · doi:10.1111/j.1542-4758.2006.01168.x · Cited by 139 · cited 1×
“Hypertriglyceridemia is one of the most common quantitative lipid abnormalities in patients with CKD [20-22].”
BackgroundImpaired metabolism of high density lipoprotein in uremic patients
Shoji, T., Nishizawa, Y., Nishitani, H., Yamakawa, M., & Morii, H. (1992) · Kidney International · doi:10.1038/ki.1992.238 · Cited by 127 · cited 2×
“However, the studies that tested the role of heparin in the pathogenesis of HD-induced dyslipidemia revealed contradictory results [40-42].”
BackgroundResultBredie, S. J. H., Bosch, F. H., Demacker, P. N. M., Stalenhoef, A. F. H., & van Leusen, R. (2001) · Peritoneal Dialysis International · doi:10.1177/089686080102100308 · Cited by 125 · cited 2×
“[49] Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R.”
BackgroundExcess parathyroid hormone adversely affects lipid metabolism in chronic renal failure
Akmal, M., Kasim, S. E., Soliman, A. R., & Massry, S. G. (1990) · Kidney International · doi:10.1038/ki.1990.58 · Cited by 123 · cited 2×
“[33] Akmal M, Kasim SE, Soliman AR, Massry SG.”
BackgroundDown-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure
Vaziri, N. D., & Liang, K. (1996) · Kidney International · doi:10.1038/ki.1996.515 · Cited by 118 · cited 1×
“The reduced catabolic rate is likely due to diminished lipoprotein lipase activity as a consequence of the downregulation of the enzyme gene [27] and the presence of lipase inhibitors [28].”
BackgroundKronenberg, F., Trenkwalder, E., Lingenhel, A., Friedrich, G. J., Lhotta, K., Schober, M., Moes, N., König, P., Utermann, G., & Dieplinger, H. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37150-9 · Cited by 116
Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD
Koren, M. J., Davidson, M. H., Wilson, D. J., Fayyad, R. S., Zuckerman, A., & Reed, D. P. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.11.025 · Cited by 115
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Navaneethan, S. D., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D. W., Craig, J. C., & Strippoli, G. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784 · Cited by 114 · cited 1×
“Interestingly, the rate of adverse events was similar in patients receiving statins and placebo.”
BackgroundHepatic HDL receptor, SR-B1 and Apo A-I expression renal failure
Vaziri, N. D., Deng, G., & Liang, K. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.6.1462 · Cited by 113 · cited 12×
“Several epidemiological studies have demonstrated that HDL cholesterol is a negative risk factor for atheroscerosis [89].”
BackgroundInfluentialUrinary Excretion of Apo(a) Fragments: Role in Apo(a) Catabolism
Kostner, K. M., Maurer, G., Huber, K., Stefenelli, T., Dieplinger, H., Steyrer, E., & Kostner, G. M. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.8.905 · Cited by 110
Tonelli, M. A., Collins, D. E., Robins, S. J., Bloomfield, H. E., & Curhan, G. C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00862.x · Cited by 107 · cited 2×
“[133] Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC.”
BackgroundLipid and lipoprotein metabolism in chronic kidney disease.
Kaysen, G. A. (2009) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2008.10.011 · Cited by 102 · cited 2×
“CKD is characterized by specific metabolic abnormalities of plasma lipoproteins [18, 19].”
BackgroundDown-regulation of hepatic LDL receptor expression in experimental nephrosis
Vaziri, N. D., & Liang, K. H. (1996) · Kidney International · doi:10.1038/ki.1996.388 · Cited by 102 · cited 1×
“Although the nature of this deficiency has not been fully characterized, studies in experimental animals have shown that the inefficient translation and/or the increased LDL-receptor protein turnover may represent the most important causes for its development [53, 54].”
BackgroundIn vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients
Frischmann, M. E., Kronenberg, F., Trenkwalder, E., Schaefer, J. R., Schweer, H., Dieplinger, B., Koenig, P., Ikewaki, K., & Dieplinger, H. (2007) · Kidney International · doi:10.1038/sj.ki.5002131 · Cited by 101 · cited 2×
“The malnutrition and inflammation and, mainly, the decreased clearance of apo(a) in HD patients, have been implicated in this procedure [80-83].”
BackgroundVaziri, N. D., Sato, T., & Liang, K. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00911.x · Cited by 99 · cited 1×
“Although the nature of this deficiency has not been fully characterized, studies in experimental animals have shown that the inefficient translation and/or the increased LDL-receptor protein turnover may represent the most important causes for its development [53, 54].”
BackgroundPrevalence of dyslipidemic risk factors in hemodialysis and CAPD patients
Kronenberg, F., Lingenhel, A., Neyer, U., Lhotta, K., König, P., Auinger, M., Wiesholzer, M., Andersson, H., & Dieplinger, H. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.23.x · Cited by 98 · cited 4×
“On the other hand, CAPD patients exhibit a more atherogenic lipid profile that is characterized by higher total and LDL cholesterol values and increased concentrations of small dense LDL and apolipoprotein B [47, 60, 62].”
BackgroundInfluentialCardiovascular risk factors in patients with chronic kidney disease
van der Zee, S. A., Baber, U., Elmariah, S., Winston, J. A., & Fuster, V. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.121 · Cited by 98 · cited 2×
“[11] van der Zee S, Baber U, Elmariah S, Winston J, Fuster V.”
BackgroundChan, D. T., Dogra, G. K., Irish, A. B., Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900003-jlr200 · Cited by 95
Abnormalities of Glucose Metabolism in Patients With Early Renal Failure
Sechi, L. A., Catena, C., Zingaro, L., Melis, A., & De Marchi, S. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1226 · Cited by 91 · cited 3×
“[24] Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S.”
BackgroundLow-density lipoprotein subfraction profiles in chronic renal failure
Rajman, I., Harper, L., McPake, D., Kendall, M. J., & Wheeler, D. C. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.9.2281 · Cited by 91
Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome.
De Sain-Van Der Velden, M. G., Reijngoud, D. J., Kaysen, G. A., Gadellaa, M. M., Voorbij, H., Stellaard, F., Koomans, H. A., & Rabelink, T. J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v981474 · Cited by 85
Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia.
Guarnieri, G., Moracchiello, M., Campanacci, L., Ursini, F., Ferri, L., Valente, M., & Gregolin, C. S. (1978) · PubMed · Cited by 85
Cheung, A. K., Parker, C. J., Ren, K., & Iverius, P. (1996) · Kidney International · doi:10.1038/ki.1996.192 · Cited by 85 · cited 2×
“[28] Cheung AK, Parker CJ, Ren K, Iverius PH.”
BackgroundDialysis modalities and dyslipidemia
Attman, P., Samuelsson, O. G., Johansson, A., Moberly, J. B., & Alaupovic, P. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.3.x · Cited by 85 · cited 3×
“[39] Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P.”
BackgroundApolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis
Attman, P., Samuelsson, O. G., Moberly, J. B., Johansson, A., Ljungman, S., Weiss, L. G., Knight‐Gibson, C., & Alaupovic, P. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00375.x · Cited by 85
KLAUSEN, K. P., SCHARLING, H., & JENSEN, J. S. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01679.x · Cited by 83 · cited 2×
“[8] Klausen KP, Scharling H, Jensen JS.”
BackgroundSerum paraoxonase activity in uremic predialysis and hemodialysis patients
Dirican, M., Akca, R., Sarandöl, E., & Dilek, K. (2004) · Journal of Nephrology · doi:10.1093/joneph/17.6.813 · Cited by 83 · cited 2×
“in the activities of HDL-associated enzymes, such as paraoxonase (an enzyme that inhibits the LDL oxidation) [95, 96].”
BackgroundShearer, G. C., Stevenson, F. T., Atkinson, D. N., Jones, H. B., Staprãns, I., & Kaysen, G. A. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00478.x · Cited by 82 · cited 2×
“In addition, other factors such as hypoalbuminemia and proteinuria may further decrease the efficiency of lipoprotein lipase-induced lipolysis of triglyceride-rich lipoproteins by interfering with the endothelial binding of the enzyme and by changing the composition of VLDLs in a way that reduces their suitability as…”
BackgroundMechanisms for increased cardiovascular disease in chronic kidney dysfunction
Yamamoto, S., & Kon, V. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328327b360 · Cited by 82 · cited 1×
“On the other hand, it is well documented that cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with CKD [2-6].”
BackgroundDyslipidemia of kidney disease
Attman, P., & Samuelsson, O. G. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832dd832 · Cited by 79 · cited 1×
“Hypertriglyceridemia is one of the most common quantitative lipid abnormalities in patients with CKD [20-22].”
BackgroundSecondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure
Vaziri, N. D., Wang, X. Q., & Liang, K. (1997) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1997.273.6.f925 · Cited by 77 · cited 1×
“It was also suggested that secondary hyperparathyroidism is involved in the impaired catabolism of triglyceride-rich lipoproteins, provided an additional mechanism by which CKD may raise plasma triglyceride concentrations [33, 34].”
BackgroundApo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure
Stenvinkel, P., Heimbürger, O., Tuck, C. H., & Berglund, L. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00880.x · Cited by 76 · cited 3×
“The isoform-specific increase in plasma Lp(a) was also observed in HD patients [79, 80].”
BackgroundIncreased lipoprotein(a) concentrations in chronic renal failure.
Haffner, S. M., Gruber, K. K., Aldrete, G., Morales, P. A., Stern, M. P., & Tuttle, K. R. (1992) · Journal of the American Society of Nephrology · doi:10.1681/asn.v351156 · Cited by 76
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis
Vaziri, N. D., & Liang, K. H. (1995) · Kidney International · doi:10.1038/ki.1995.500 · Cited by 76 · cited 1×
“Indeed, studies in animals with experimental nephrosis revealed an upregulation of HMG-CoA reductase [57] as well as a relative reduction of cholesterol 7 -hydroxylase [58].”
BackgroundSmall Apolipoprotein(a) Size Predicts Mortality in End-Stage Renal Disease: The CHOICE Study
Longenecker, J. C., Klag, M. J., Marcovina, S. M., Powe, N. R., Fink, N. E., Giaculli, F., & Coresh, J. (2002) · Circulation · doi:10.1161/01.cir.0000038946.91899.bb · Cited by 70 · cited 2×
“[78] Longenecker JC, Klag MJ, Marcovina SM, et al.”
BackgroundWanner, C., Bahner, U., Mattern, R., Lang, D., & Passlick‐Deetjen, J. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh415 · Cited by 69 · cited 2×
“[45] Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J.”
BackgroundKagan, A., Bar‐Khayim, Y., Schafer, Z., & FAINARU, M. (1990) · Kidney International · doi:10.1038/ki.1990.74 · Cited by 67 · cited 2×
“[66] Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M.”
BackgroundFibrates: What Have We Learned in the Past 40 Years?
Backes, J. M., Gibson, C. A., Ruisinger, J. F., & Moriarty, P. M. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.412 · Cited by 63 · cited 2×
“These drugs modify the expression of genes involved in lipoprotein metabolism and thus they reduce the concentrations of triglycerides, increase the serum concentrations of HDL-cholesterol and induce a shift in LDL subfraction distribution towards larger and more buoyant particles [130].”
BackgroundUp-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome
Vaziri, N. D., & Liang, K. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00319.x · Cited by 63 · cited 1×
“cholesterol esterification in hepatocytes) that has been observed in individuals with NS [56] may reduce the free cholesterol content of hepatocytes and thus may lead to the dysregulation of the key enzymes that are involved in cholesterol homeostasis.”
BackgroundHypertriglyceridemia in patients with chronic renal failure: Possible mechanisms
Prinsen, B. H. C. M. T., der Velden, M. G. M. D. S., de Koning, E. J. P., Koomans, H. A., Berger, R., & Rabelink, T. J. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s84.34.x · Cited by 63 · cited 3×
“Except of the low catabolic rate, the increased hepatic production of triglyceriderich lipoproteins may also play a contributory role in the pathogenesis of dyslipidemia in renal disease [26].”
BackgroundInfluentialApolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure
Milionis, H. J., Elisaf, M., Tselepis, A. D., Bairaktari, E. T., Karabina, S., & Siamopoulos, K. C. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70147-2 · Cited by 58 · cited 4×
“Lp(a) represents an LDL-like particle distinguished from LDL by the presence of apolipoprotein(a) [apo(a)], which is attached to apolipoprotein B-100 molecule through disulfide linkage [69].”
BackgroundInfluentialSelf-citationHirano, T., Sakaue, T., Misaki, A., Murayama, S., Takahashi, T., Okada, K., Takeuchi, H. T., Yoshino, G., & Adachi, M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00019.x · Cited by 57
Kimura, H., Miyazaki, R., Imura, T., Masunaga, S., Suzuki, S., Gejyo, F., & Yoshida, H. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00285.x · Cited by 56 · cited 2×
“Thus, patients with impaired renal function usually exhibit decreased levels of apolipoproteins AI and AII (the main protein constituents of HDL) [91], diminished activity of LCAT (the enzyme responsible for the esterification of free cholesterol in HDL particles) [92, 93], as well as increased activity of cholesteryl…”
BackgroundLipid Changes and Statins in Chronic Renal Insufficiency
Ritz, E., & Wanner, C. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080919 · Cited by 54 · cited 1×
“Thus, it has been suggested that the initiation and progression of atherosclerotic disease in this population may have a different pathophysiological basis (arterial wall calcification, inflammation etc), whereas other investigators emphasize that lipoproteins other than LDL (such as Lp(a), IDL etc) may play significa…”
BackgroundInsulin resistance and postprandial triglyceride levels in primary renal disease
CHARLESWORTH, J. A., Kriketos, A. D., Jones, J. E., Erlich, J., Campbell, L. V., & Peake, P. W. (2005) · Metabolism · doi:10.1016/j.metabol.2005.01.028 · Cited by 51 · cited 3×
“It is well known that CKD causes insulin resistance which can, in turn, promote hepatic VLDL production [23-25].”
BackgroundVega, G. L., Toto, R. D., & Grundy, S. M. (1995) · Kidney International · doi:10.1038/ki.1995.73 · Cited by 49 · cited 1×
“Hypertiglyceridemia [due to accumulation of VLDL and remnant lipoproteins such as intermediate-density lipoprotein (IDL)], is also the predominant lipoprotein abnormality in a considerable number of cases with nephrotic range proteinuria [35].”
BackgroundDeighan, C. J., Caslake, M. J., McConnell, M., Boulton-Jones, J. M., & Packard, C. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00710-3 · Cited by 48 · cited 2×
“[55] Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM,”
BackgroundGoldfarb‐Rumyantzev, A. S., Habib, A. N., Baird, B. C., Barenbaum, L. L., & Cheung, A. K. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.07.023 · Cited by 47 · cited 2×
“[124] Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK.”
ResultLemos, P. A., Serruys, P. W. J. C., de Feyter, P. J., Mercado, N. F., Goedhart, D. M., Saia, F., Arampatzis, C. A., Soares, P. R., Ciccone, M. M., Arquati, M., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.008 · Cited by 45 · cited 2×
“[113] Lemos PA, Serruys PW, de Feyter P, et al.”
BackgroundDyslipidemia in Peritoneal Dialysis — Relation to Dialytic Variables
Johansson, A., Samuelsson, O. G., Attman, P., Haraldsson, B. S., Moberly, J. B., Knight‐Gibson, C., & Alaupovic, P. (2000) · Peritoneal Dialysis International · doi:10.1177/089686080002000307 · Cited by 44 · cited 7×
“[48] Johansson AC, Samuelsson O, Attman PO, et al.”
BackgroundInfluentialWanner, C., Bartens, W., Walz, G., Nauck, M., & Schollmeyer, P. J. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a090858 · Cited by 38 · cited 2×
“[85] Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P.”
BackgroundTrenkwalder, E., Gruber, A. C., König, P., Dieplinger, H., & Kronenberg, F. (1997) · Kidney International · doi:10.1038/ki.1997.503 · Cited by 36
Addabbo, F., Mallamaci, F., Leonardis, D., Tripepi, R., Tripepi, G., Goligorsky, M. S., & Zoccali, C. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm418 · Cited by 36 · cited 2×
“[15] Addabbo F, Mallamaci F, Leonardis D, et al.”
BackgroundExpert Commentary: The Safety of Fibrates in Lipid-Lowering Therapy
Brown, W. V. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.017 · Cited by 35
Shoji, T., & Nishizawà, Y. (2006) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2006.00382.x · Cited by 34 · cited 1×
“Thus, it has been suggested that the initiation and progression of atherosclerotic disease in this population may have a different pathophysiological basis (arterial wall calcification, inflammation etc), whereas other investigators emphasize that lipoproteins other than LDL (such as Lp(a), IDL etc) may play significa…”
BackgroundHoldaas, H., Wanner, C., Abletshauser, C., Gimpelewicz, C. R., & Isaacsohn, J. L. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.06.003 · Cited by 33 · cited 1×
“The same results were also obtained by the study of the prespecified subgroups of individuals with impaired renal function in the HPS [109, 119] and ASCOT-LLA [120] studies that utilized simvastatin and atorvastatin, respectively.”
ResultMultiple biomarkers for the prediction of first major cardiovascular events and death
Wang, T. J., Gona, P. N., & Larson, M. G. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.01.008 · Cited by 33
Apolipoprotein C-III, Hypertriglyceridemia and Triglyceride-Rich Lipoproteins in Uremia
Moberly, J. B., Attman, P., Samuelsson, O. G., Johansson, A., Knight‐Gibson, C., & Alaupovic, P. (1999) · Mineral and Electrolyte Metabolism · doi:10.1159/000057457 · Cited by 32 · cited 2×
“A decrease in apolipoprotein C-II/C-III ratio due to a disproportionate increase in plasma apolipoprotein C-III is a possible cause of lipoprotein lipase inactivation in uremia [29-32].”
BackgroundDyslipidemias in Patients Who Have Chronic Kidney Disease
Farbakhsh, K., & Kasiske, B. L. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.11.002 · Cited by 32 · cited 1×
“In HD patients the serum lipid concentrations resemble those of predialysis patients with CKD, which means that total and LDL cholesterol levels are generally normal, whereas the subfractionation of apolipoprotein B-containing lipoproteins usually reveals a predominance of small dense particles [60, 61].”
BackgroundLiberopoulos, E. N., Papavasiliou, E. C., Miltiadous, G. A., Cariolou, M. A., Siamopoulos, K. C., Tselepis, A. D., & Elisaf, M. (2004) · Peritoneal Dialysis International · doi:10.1177/089686080402400618 · Cited by 23 · cited 2×
“[96] Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al.”
BackgroundSelf-citationSerum Lp(a) Levels in Patients with Moderate Renal Failure
Bairaktari, E. T., Elisaf, M., Tsolas, O., & Siamopoulos, K. C. (1998) · The Nephron journals/Nephron journals · doi:10.1159/000045073 · Cited by 17 · cited 2×
“Thus, it is not surprising that patients with primary kidney diseases (even those with normal GFR values) usually exhibit markedly elevated concentrations of Lp(a) [73, 74] as well as increased concentrations of LDL-unbound apo(a) [75].”
BackgroundSelf-citation
Cited by
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
de Ferranti, S. D., Steinberger, J., Ameduri, R., Baker, A., Gooding, H., Kelly, A. S., Mietus-Snyder, M., Mitsnefes, M. M., Peterson, A. L., St-Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 441
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Metadata
- Authors
- Tsimihodimos, V., Mitrogianni, Z., & Elisaf, M.
- Venue
- The Open Cardiovascular Medicine Journal
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-02-24
- Volume
- 5
- Issue
- 1
- Pages
- 41-48
- ISSN
- 1874-1924 (ISSN-L)
- OpenAlex
- W2170911164
- Cited by
- 174
- References
- 120
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.